Appian International Research Enters Second Year with Ongoing Trials in Seven Countries
Appian International Research Enters Second Year with Ongoing Trials in Seven Countries
CHARLOTTE, NC, June 29, 2007-This week, Appian International Research, Inc. announced plans to expand its generic pharmaceuticals development services as the company enters its second year.
“Appian International Research as a company is still relatively new to the industry, but our team certainly isn’t,” explained Appian’s President, Dr. Grier Harris.
“Appian International Research is the outgrowth of Appian Services, a consulting firm that we established in 2003 to provide contract development services to generic and small Pharma companies. We help our clients manage strategic development plans, designed study protocols, compiled reports, and performed site audits, whatever it took to help them overcome the hurdles inherent in pharmaceutical product development. As business grew, we decided to focus on our expanding network of international resources and broaden our range of services.”
“Our specialty, of course, is the design and management of clinical endpoint bioequivalence trials, the sort of trials that the FDA’s Office of Generic Drugs requires for the approval of topically active drugs. Most of our early work has been in dermatological products, but we are currently expanding into some other therapeutic areas that will take advantage of the many years of experience that we have in topical drug development.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
